IL9 and neoplasm: These drugs, in combination with therapies aimed at neutralizing the T cell suppressive activities of IL-6, IL-9 and/or IL-10, may reasonably help reducing immune evasion of tumor cells, thereby ameliorating the clinical management of the disease.